Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Principal Investigator Positions at CeMM in Vienna

    Are you full of ideas and impatient for action to translate the opportunities of the genomic age into better therapeutics and diagnostics?
    Do you have a truly collaborative mindset and enjoy teamwork across disciplines?
    Do you have an inclusive and open personality that cherishes being a scientist within a broader cultural and social context?

    CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, is one of the best places you should consider to advance your basic, medical-oriented research.

    We are a group of 130 scientists from 34 nations working at the interface of basic research and medicine in the areas of inflammation/infection/immunity, cancer and metabolic disorders. We are situated in a beautiful, bright and perfectly designed building (inaugurated in 2011), with outstanding design and state-of-the-art laboratories, strategically located next to one of the world’s largest research hospital. Vienna is one of Europe’s most fascinating capitals, with world-best quality of life, legendary music and culture. CeMM has been voted best place to work in academia in a 2012 survey by The Scientist. CeMM is an equal opportunity employer. The official language at CeMM is English.

    Within our short life, based on our super-cooperative research mode and –omics technologies, we have already identified the missing cancer gene in myeloproliferative neoplasms (Klampfl et al. NEJM 2013), a new cancer pathway with a new drug (Huber et al. Nature 2014), as well as the molecular basis for acute macular degeneration (Weismann et al. Nature 2011). The total number of publications within the last three years was 158, among more than half, 82 papers have been published in journals with an impact factor > 10 (Institute is the affiliation of the last author).

    To complement and strengthen the current faculty, CeMM is looking for outstanding individuals who work on an exciting problem of molecular medicine, preferably but not exclusively pertaining to Innate Immunity, Infection Biology, Inflammation, Hematopoiesis, Hematological Malignancies, Genome Integrity, Blood, Vascular Disorders or Metabolic Disorders. Approaches that we are particularly interested in are: Systems Biology, Bioinformatics, Immunotherapy, Genomics, Epigenetics, Metabolomics, Chemical Biology, High-Content Screening, Single-Cell Technologies.

    We are looking for MD and/or PhD scientists either at their first independent appointment or already at the consolidation stage to apply their expertise close to a clinical setting in a stimulating research environment.

    Initial appointments for starting PIs are for five years but are expected to be extended after reviewing for an additional term of three years, subject to review by the Scientific Advisory Board. Consolidated researchers can expect to enter a rolling five-year appointment after the initial five. CeMM PIs have access to state-of-the-art chemical screening, proteomics, NGS, SPF mouse facility, imaging, haploid cell genetics and cell sorting. CeMM and the Medical University of Vienna are actively supporting dual appointments. Conditions are commensurate to experience and needs, include a start-up package and support for a core group.

    Required are an MD or PhD degree, scientific quality and originality, a track record of achievements as well as a collaborative and interdisciplinary mindset. Applications should be in English and contain a CV, publication list, funding track record or funding plans, names and addresses of three references, a short summary of research interests and objectives (max. 3 pages). Please also summarize in one paragraph what you believe your single greatest research achievement has been so far and why.

    Please send all documents in English, mentioning the code CPI2014 or SPI2014, to: Anita Ender, [email protected]; www.cemm.at;
    Application deadline: September 15, 2014

    Informal inquiries can be addressed to Sylvia Knapp ([email protected]), Denise Barlow ([email protected]), or Giulio Superti-Furga ([email protected]).

Latest Articles

Collapse

  • seqadmin
    Essential Discoveries and Tools in Epitranscriptomics
    by seqadmin




    The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...
    04-22-2024, 07:01 AM
  • seqadmin
    Current Approaches to Protein Sequencing
    by seqadmin


    Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
    04-04-2024, 04:25 PM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, Yesterday, 11:49 AM
0 responses
13 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-24-2024, 08:47 AM
0 responses
16 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-11-2024, 12:08 PM
0 responses
61 views
0 likes
Last Post seqadmin  
Started by seqadmin, 04-10-2024, 10:19 PM
0 responses
60 views
0 likes
Last Post seqadmin  
Working...
X